Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Verve Therapeutics, Inc. for Potential Violations of Federal Securities Laws
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Verve Therapeutics, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims
on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws.
紐約，2024 年 4 月 19 日 /PRNewswire/ — 卓越的全國股東權益訴訟公司沃爾夫·哈爾登斯坦·阿德勒·弗里曼和赫茲律師事務所（“Wolf Haldenstein”）宣佈正在調查索賠
代表Verve Therapeutics, Inc.（“Verve” 或 “公司”）（納斯達克股票代碼：VERV）違反證券法的投資者。
The focus of the investigation is to whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
調查的重點是公司是否發佈了虛假和/或誤導性陳述和/或沒有披露與投資者有關的信息。
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
請點擊此處提供您的聯繫信息
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Verve is the subject of an article published by Bloomberg on April 2, 2024. According to the article, the Company "cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine."
調查的重點是公司是否發佈了虛假和/或誤導性陳述和/或未能披露與投資者有關的信息。Verve是彭博社於2024年4月2日發表的一篇文章的主題。根據這篇文章，該公司 “列舉了暫停註冊一項針對高膽固醇患者的基因編輯療法的研究的安全問題，這給這個前景光明的新醫學領域帶來了挫折。”
Based on this news, shares of Verve fell by more than 40% in morning trading on the same day.
根據這一消息，Verve的股價在當天早盤交易中下跌了40％以上。
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville, and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
沃爾夫·哈爾登斯坦在全國各地的州和聯邦審判和上訴法院起訴證券集體訴訟和衍生訴訟方面擁有經驗。該公司在各個業務領域都有律師，並在紐約、芝加哥、納什維爾和聖地亞哥設有辦事處。這家公司在股東和其他集體訴訟中的聲譽和專業知識一再受到法院的稱讚，法院已任命其在複雜證券、多地區和合並訴訟中擔任重要職務。
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
如果您想討論此項行動或對本案中的權益有任何疑問，請立即致電 (800) 575-0735或發送電子郵件至 [email protected] 與沃爾夫·哈爾登斯坦聯繫。
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
聯繫人：
Wolf Haldenstein Adler Freeman & Herz LLP
格雷戈裏·斯通，案例與財務分析總監
電子郵件：[電子郵件保護] 或 [電子郵件保護]
電話：(800) 575-0735 或 (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
根據適用的法律和道德規則，本新聞稿在某些司法管轄區可能被視爲律師廣告。
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
來源 Wolf Haldenstein Adler Freeman & Herz LLP
譯文內容由第三人軟體翻譯。